A Call for Papers on Human Subjects by Bell, Jennifer
T
h
e
 
J
o
u
r
n
a
l
 
o
f
 
E
x
p
e
r
i
m
e
n
t
a
l
 
M
e
d
i
c
i
n
e
 
Editorial
 
J. Exp. Med. 
 

 
 The Rockefeller University Press • 0022-1007/2003/12/1621/1 $8.00
Volume 198, Number 11, December 1, 2003 1621
http://www.jem.org/cgi/doi/10.1084/jem.20031882
 
1621
 
Research on human subjects is currently
 
represented in only a fraction of the
 
papers published in the 
 
JEM
 
, but the
Editors and I would like that to
change. Given recent advances, such
as new techniques to precisely and
quantitatively monitor human immune
responses and new drugs that act on
increasingly well-defined pathways, it
is now more feasible to perform exciting
research on human subjects.
Investigators who carry out research
on humans often struggle to publish
 
important findings in widely read jour-
nals. Everyone realizes that a researcher
 
cannot typically achieve the same
level of mechanistic depth and proof
in human studies relative to more
tractable animal and in vitro systems.
Yet, there is a need to study human
subjects to make discoveries that are
directly applicable to the diagnosis,
prevention, and treatment of human
disease. It is clear that animal models
of disease, where they exist, do not al-
ways reliably recapitulate the mecha-
nisms and clinical features of human
disease, and in many cases the pathol-
ogy is quite different. Thus, the preci-
sion lost in human studies owing to
limited subject number and uncontrol-
lable variables is gained in relevance to
human disease. The Editors of the
 
JEM
 
 do not regard this research as
translational in a literal sense, that is,
extending lessons from mice to men.
Rather, we view research on humans
as de novo research on disease processes
in man.
 
We would like to publish more
research on human subjects in areas
such as infection, hematopoiesis, malig-
nancy, autoimmunity, and allergy, tradi-
tionally  highlighted by the 
 
Journal
 
.
Two types of manuscripts are antici-
pated: (i) studies which identify new
features of the disease process in humans
and (ii) investigations of patient re-
sponses to approved experimental
treatments or vaccines. Each paper
 
will be judged in the context of human
research, taking into account the sig-
nificance of the problem that is being
tackled and the challenges of the clinical
setting. Studies involving a small num-
ber of subjects will be considered if
they are of high quality and importance.
As always, we will prioritize papers
that provide new mechanistic insights.
The process of peer review will assess
the suitability of the assays and the
validity of the experimental design.
We are pleased to welcome on board
two new Consulting Biostatistics Ed-
itors, Drs. Glenn Heller and Madhu
Mazumdar of the Memorial Sloan-
Kettering Cancer Center, who will
oversee expert statistical evaluations.
As stated in our instructions to au-
thors, all studies of human subjects
must be conducted according to the
principles expressed in the Helsinki
Declaration (1) and be approved by an
appropriate regulatory body, such as
an institutional review board.
We are pleased that this issue of the
 
JEM
 
 contains an example of the high
caliber, high impact research on human
subjects we would like to attract.
 
Dhodapkar et al. (2) show that T cells
can recognize and potentially control
a precursor of multiple myeloma
known as preneoplastic gammopathy.
As Olivera Finn discusses in her com-
mentary (3), the findings provide a
strong rationale for premalignancy
vaccines. The Editors and I look for-
ward to receiving more experimental
medicine of this caliber in the near
future.
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